SecBot SecBot
8-K ·Filed Nov 4, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed12d 7h ago SEC0001628280-26-070148
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Watch for topline ECLIPSE 1 Phase 3 data in Q4 2026, which is a pivotal catalyst for the CHD program. The Gilead collaboration validates the PRO-XTEN platform but adds no near-term revenue. Monitor cash burn rate and any updates on VIR-5500 pivotal trial initiation in 2027.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

VIR drug pipeline →

elebsiran

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 ECLIPSE 1 results are positive, regulatory filings could follow in 2027, with potential FDA approval in 2027-2028 given the Breakthrough Therapy designation enabling expedited review.
Next catalyst
None dated

What to watchThe pivotal Phase 3 ECLIPSE 1 topline results for elebsiran plus tobevibart in chronic hepatitis delta will be presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Positive data would support regulatory filings and validate the combination against bulevirtide; negative or mixed results would severely damage the company's lead program thesis. The stock surged ~11% on November 6 ahead of the readout, reflecting anticipation.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$11.02
T+0 close · Nov 4, 2026 · via day close
Latest settled
+9.98%
T+5 · $12.12 · next T+20 in 17d
Vs SPY
+6.69%
α at T+5
Latest observation
−13.41%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $11.02entry
  2. T+1 · 11d ago +10.80%α +10.49% · $12.21
  3. T+5 · 5d ago +9.98%α +6.69% · $12.12
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology reported Q3 2026 net loss of $96.3M ($0.57 per share), narrower than the $163.1M loss in Q3 2025, driven by a $75M non-recurring milestone expense in the prior year. The company ended the quarter with $901.3M in cash and investments, entered a Gilead collaboration for up to $1.74B in milestones, and expects topline Phase 3 ECLIPSE 1 data in Q4 2026.

Key Financial Metrics

EPS
−$0.57
Revenue
-$188.0K
est $1.4M · -113.4%

Key Facts

  • Q3 2026 net loss of $96.3M ($0.57 per share) vs $163.1M ($1.17 per share) in Q3 2025
  • Cash, cash equivalents and investments of $901.3M as of September 30, 2026, a decrease of $106.5M during Q3
  • Entered collaboration with Gilead for three PRO-XTEN dual-masked TCE candidates; received $90M upfront including $25M equity investment at 30% premium
  • VIR-5500 received FDA Fast Track designation and achieved proof of concept; pivotal trials expected to begin in 2027
  • Topline data from Phase 3 ECLIPSE 1 trial for chronic hepatitis delta expected in Q4 2026
  • Appointed Aziz Sawaf as CFO, David Liu as CMO, and Suzanne Topalian to the Board

Financial Impact

Net loss improved by $66.8M YoY; cash burn of $106.5M in Q3; Gilead deal provides $90M upfront with potential $1.74B in milestones

net losscash positionR&D expenses

Risk Factors

  • Phase 3 ECLIPSE 1 data readout in Q4 2026 carries binary risk for the CHD program
  • Cash burn of $106.5M per quarter implies runway into H2 2028, but no revenue from pipeline
  • Gilead collaboration milestones are contingent on preclinical and clinical success

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-070148
Document: vir-20261104.htm0001628280-26-070148
Document: 0001628280-26-070148-index-headers.html0001628280-26-070148
Document: 0001628280-26-070148-index.html0001628280-26-070148
Document: 0001628280-26-070148.txt0001628280-26-070148
8-K Data (Synthetic)0001628280-26-070148

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026